Proximal Ventures raises debut fund to back startups bringing AI to drug development
techcrunch.com Nov 11, 2026

Proximal Ventures raises debut fund to back startups bringing AI to drug development

AI-summarised brief · reviewed before publication

Proximal Ventures, led by former SignalFire investor Sahir Raoof, secured $27.5 million for its inaugural fund, targeting startups that apply artificial intelligence to drug‑development services. Raoof argues AI can automate tasks traditionally outsourced by pharma—such as compound synthesis, manufacturing scale‑up, and clinical data analysis—reducing cost and time. The fund will place pre‑seed and seed checks of $500,000 to $1.5 million, and has already invested in seven companies, including ChronicleBio. Backers include SignalFire, Kleiner Perkins, and industry experts like Amy Abernethy.

💡 Why It Matters

  • · By funding AI‑driven service startups, Proximal Ventures could reshape the pharmaceutical supply chain, accelerating drug development and unlocking new revenue streams for life‑science companies.